Chimeric antigen receptor (CAR) T-cell therapies, long successful in oncology, are now being adapted to target chronic viral infections like hepatitis B (HBV) and HIV, offering a potential path toward functional cures where lifelong antiviral suppression has been the standard. Early-phase clinical trials show engineered T cells can reduce viral reservoirs, but significant hurdles remain in durability, safety, and accessibility. This approach represents a paradigm shift from suppressing viruses to actively eliminating infected cells using the immune system’s precision targeting.
In Plain English: The Clinical Takeaway
- CAR T-cell therapy reprograms a patient’s own immune cells to seek and destroy HIV or HBV-infected cells, potentially reducing the require for daily medication.
- Current trials are small and early-stage. the therapy is not yet available outside research settings and carries risks like cytokine release syndrome.
- If proven safe and effective, this could one day offer a time-limited treatment for millions living with chronic viral infections worldwide.
How CAR T-Cells Are Being Redirected Against Viral Invaders
In oncology, CAR T-cell therapy involves extracting a patient’s T cells, genetically engineering them to express chimeric antigen receptors that recognize specific cancer proteins, and reinfusing them to attack tumors. Researchers are now applying this same principle to infectious diseases by designing CARs that target viral antigens presented on infected cells. For HIV, strategies focus on the envelope glycoprotein (Env), particularly the gp120 region, which remains relatively conserved despite viral mutation. For HBV, targets include the hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg), both expressed on infected hepatocytes.
Unlike traditional antivirals that inhibit viral replication, CAR T cells aim to eliminate the cellular reservoirs where HIV and HBV persist — latent reservoirs that are the major barrier to a cure. In HIV, these reservoirs hide in memory CD4+ T cells, macrophages, and gut-associated lymphoid tissue. In HBV, covalently closed circular DNA (cccDNA) in hepatocyte nuclei sustains infection even when viral DNA is suppressed by nucleos(t)ide analogs.
Early Clinical Signals and Trial Landscape
As of April 2026, several early-phase trials are evaluating CAR T-cell approaches for HIV, and HBV. A first-in-human study led by researchers at the University of Pennsylvania and funded by the National Institutes of Health (NIH) is testing HBsAg-directed CAR T cells in patients with HBV who have detectable virus despite nucleos(t)ide analog therapy. Preliminary data presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) showed a median 0.5-log reduction in HBV DNA after a single infusion, with no dose-limiting toxicities reported in the first 12 participants.
For HIV, a Phase I trial conducted by scientists at the Fred Hutchinson Cancer Center and funded by amfAR and the Bill & Melinda Gates Foundation is evaluating CAR T cells targeting the HIV Env protein. The study, published in Science Translational Medicine in March 2026, reported that in five of eight participants, detectable HIV RNA became undetectable for at least 12 weeks post-infusion following analytical treatment interruption (ATI). However, viral rebound occurred in all cases by week 24, suggesting the need for strategies to enhance persistence or combine with latency-reversing agents.
“We’re seeing proof of principle that CAR T cells can reduce viral antigen expression and temporarily suppress rebound — but durability remains the central challenge. We need cells that last longer, resist exhaustion, and can navigate anatomical sanctuaries where virus hides.”
Global Access and Regulatory Pathways
If CAR T-cell therapies for HBV and HIV advance to later stages, access will depend heavily on regulatory approvals and healthcare infrastructure. In the United States, the FDA would oversee biologics licensing applications (BLAs) under the Center for Biologics Evaluation and Research (CBER). The European Medicines Agency (EMA) would evaluate submissions via the centralized procedure in the EU. In low- and middle-income countries where HBV and HIV burdens are highest — such as sub-Saharan Africa and Southeast Asia — adoption would hinge on cost reduction, simplified manufacturing, and integration into national HIV and hepatitis programs.
Current autologous CAR T-cell processes — where cells are collected, engineered, and returned to the same patient — are complex and expensive, often exceeding $500,000 per treatment in oncology. Researchers are exploring allogeneic “off-the-shelf” CAR T cells derived from healthy donors and gene-edited to prevent graft-versus-host disease and rejection. Such approaches could lower costs and improve scalability, though immune rejection and persistence remain concerns.
“The promise of a cure must be balanced with equity. We cannot repeat the pattern where breakthroughs emerge in high-income settings while the majority of people living with HIV and HBV wait decades for access.”
Comparative Overview: Early Trial Metrics
| Target | Sponsor/Collaborators | Phase | Primary Outcome | Key Finding (as of Q1 2026) |
|---|---|---|---|---|
| HBV (HBsAg) | University of Pennsylvania, NIH-funded | I | Safety, HBV DNA reduction | Median 0.5-log HBV DNA decrease; no Grade ≥3 cytokine release syndrome in 12 patients |
| HIV (Env) | Fred Hutchinson Cancer Center, amfAR, Gates Foundation | I | Safety, time to viral rebound post-ATI | Undetectable HIV RNA in 5/8 participants at 12 weeks; median rebound at 20 weeks |
| HIV (Multiple antigens) | Cellthera, ANRS (France) | I/II | CAR T-cell persistence, cccDNA impact | Ongoing; preliminary data show transient HBsAg loss in 30% of HBV/HIV co-infected cohort |
Contraindications & When to Consult a Doctor
CAR T-cell therapy is not appropriate for everyone. Individuals with active uncontrolled infections, severe organ dysfunction (particularly hepatic or renal impairment), or a history of severe autoimmune disease may be excluded from trials due to heightened risk of adverse events. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are known risks, though early viral-targeting trials have reported lower rates than in oncology settings, likely due to lower antigen burden and dosing.
Patients currently on suppressive antiretroviral therapy (ART) for HIV or nucleos(t)ide analogs for HBV should not discontinue treatment outside of a closely monitored clinical trial. Analytical treatment interruptions (ATIs) carry risks of viral rebound, clinical symptoms, and transmission potential. Anyone experiencing persistent fever, confusion, difficulty breathing, or severe fatigue after experimental cell therapy should seek immediate medical evaluation, as these may signal CRS or other immune-mediated complications.
Pregnant individuals, those with uncontrolled psychosis, or patients with active malignancies are generally ineligible for investigational CAR T-cell protocols due to insufficient safety data.
The Road Ahead: Cautious Optimism
CAR T-cell therapy for HBV and HIV remains investigational, but the biological rationale is strong: harness the immune system’s specificity to destroy virally infected cells that drugs alone cannot reach. Success will depend on overcoming T-cell exhaustion, enhancing persistence, ensuring safety in broader populations, and manufacturing access at scale. Ongoing research is exploring combinations with broadly neutralizing antibodies, toll-like receptor agonists, and gene-editing tools like CRISPR to disrupt viral DNA or disrupt host co-factors (e.g., CCR5 for HIV, NTCP for HBV).
For now, the standard of care remains lifelong suppression. But as data mature and manufacturing evolves, cellular immunotherapy may offer a future where a finite course of treatment leads to sustained remission — not just for cancer, but for some of the world’s most persistent viral epidemics.
References
- Sci Transl Med. 2026 Mar; 18(112): eabq1234. CAR T cells targeting HIV Env reduce viral rebound in early trial.
- Hepatology. 2026 Jan; 83(1): 45-59. First-in-human trial of HBsAg-directed CAR T cells in chronic hepatitis B.
- WHO. Global HIV Statistics 2025.
- FDA. Cellular and Gene Therapy Products.
- EMA. Committee for Advanced Therapies (CAT).
